Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
J Am Acad Dermatol
; 27(1): 65-9, 1992 Jul.
Article
en En
| MEDLINE
| ID: mdl-1619079
ABSTRACT
BACKGROUND:
Intralesional interferon has shown activity in the treatment of noduloulcerative and superficial basal cell carcinomas (BCC).OBJECTIVE:
Our purpose was to study the efficacy of intralesional interferon in the treatment of aggressive BCCs.METHODS:
Fifteen patients with histologically proven primary morpheaform or recurrent BCCs were referred for Mohs surgery. They received nine intralesional injections of 1.5 million IU of interferon alfa-2b three times a week for 3 weeks (total dose 13.5 million IU). All tumors were located on the face and measured 7 to 25 mm in diameter.RESULTS:
In four patients (27%) no residual tumor was found at surgery. In five (33%) tumor size was reduced by 75%. The remaining six patients (40%) showed no response to intralesional interferon.CONCLUSION:
At the dosage used, interferon was able to cure only a minority of aggressive BCCs.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Neoplasias Faciales
/
Carcinoma Basocelular
/
Interferón-alfa
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
1992
Tipo del documento:
Article
País de afiliación:
Suecia